Although radioactive nucleotides are the most feasible biomarkers for screening of PD [231], fluid biomarkers, neuromelanin antibodies, candidate blood-based biomarker testing (e.g. SNCA, DJ-1, uric acid, epidermal growth factor, ApoA1) [232], gene expression profiling, metabolomics, protein profiling (e.g. Aβ and tau) and inflammatory markers (e.g. IL-6) from blood and CSF samples, can be used to predict PD. Here, EGF is linked to Parkinson disease.